Total Payments
$555,094
2024 Payments
$94,139
Companies
38
Transactions
427
Medicare Patients
721
Medicare Billing
$76,262
Payment Breakdown by Category
Consulting$417,373 (75.2%)
Research$85,758 (15.4%)
Travel$23,894 (4.3%)
Other$22,863 (4.1%)
Food & Beverage$5,191 (0.9%)
Education$15.27 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $417,373 | 231 | 75.2% |
| Unspecified | $85,758 | 62 | 15.4% |
| Travel and Lodging | $23,894 | 46 | 4.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,863 | 8 | 2.7% |
| Honoraria | $8,000 | 3 | 1.4% |
| Food and Beverage | $5,191 | 76 | 0.9% |
| Education | $15.27 | 1 | 0.0% |
Payments by Type
General
$469,336
365 transactions
Research
$85,758
62 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $95,399 | 30 | $0 (2024) |
| Biogen, Inc. | $72,215 | 28 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $50,510 | 32 | $0 (2024) |
| ABBVIE INC. | $32,440 | 18 | $0 (2021) |
| Janssen Research & Development, LLC | $26,867 | 24 | $0 (2023) |
| GlaxoSmithKline, LLC. | $26,445 | 12 | $0 (2024) |
| AstraZeneca UK Limited | $26,099 | 24 | $0 (2024) |
| PFIZER INC. | $25,005 | 37 | $0 (2024) |
| Octapharma USA, Inc. | $21,802 | 25 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $20,620 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $94,139 | 72 | GENZYME CORPORATION ($24,159) |
| 2023 | $102,554 | 58 | GENZYME CORPORATION ($59,037) |
| 2022 | $63,753 | 58 | E.R. Squibb & Sons, L.L.C. ($12,885) |
| 2021 | $77,882 | 43 | ABBVIE INC. ($15,192) |
| 2020 | $43,016 | 25 | Biogen, Inc. ($13,264) |
| 2019 | $45,005 | 49 | Biogen, Inc. ($10,894) |
| 2018 | $68,628 | 63 | Biogen, Inc. ($19,582) |
| 2017 | $60,117 | 59 | Biogen, Inc. ($15,186) |
All Payment Transactions
427 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Kyowa Kirin Co., Ltd | — | Consulting Fee | Cash or cash equivalent | $1,410.00 | General |
| 12/18/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,920.00 | General |
| 12/10/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $67.77 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $47.71 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.62 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.99 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,125.00 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $849.64 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/20/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $35.25 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $742.17 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | Kyowa Kirin Co., Ltd | — | Consulting Fee | Cash or cash equivalent | $940.00 | General |
| 11/15/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $120.67 | General |
| 11/15/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $7.74 | General |
| 10/24/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Consulting Fee | Cash or cash equivalent | $4,654.97 | General |
| Category: IMMUNOLOGY | ||||||
| 10/04/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,491.24 | General |
| 09/20/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $479.14 | General |
| 09/20/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $164.25 | General |
| 09/20/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $66.73 | General |
| 09/19/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $151.72 | General |
| 09/19/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $99.30 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 09/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $3,928.35 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $1,281.60 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/19/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $305.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus | ABBVIE INC. | $15,192 | 7 |
| M19-130 | AbbVie Inc. | $11,903 | 4 |
| GAM10-08 | Octapharma USA, Inc. | $8,722 | 15 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $8,600 | 8 |
| LUPUS Study | Biogen, Inc. | $8,333 | 1 |
| LEX-209 | Octapharma USA, Inc. | $5,141 | 4 |
| A Phase 1 Randomized Double-Blind Placebo-Controlled Single Ascending Dose or Multiple Ascending Dose Study of KK4277 in Healthy Volunteers Patient With Systemic Lupus Erythematosus and Patient With Cutaneous Lupus Erythematosus | Kyowa Kirin, Inc. | $3,200 | 2 |
| PF07038124 BREPOCITINIB DAZUKIBART PF06763809 DEKAVIL PF06817024 PF06480605 RITLECITINIB ZIMLOVISERTIB PF06826647 PF06835375 MULTI PRODUCT PF07054894 PF06473871 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| Phase 2 SLE | E.R. Squibb & Sons, L.L.C. | $2,600 | 1 |
| Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) | Biogen, Inc. | $2,598 | 1 |
| Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of BMS-986165 in Participants with Systemic Lupus Erythematosus | E.R. Squibb & Sons, L.L.C. | $1,616 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID | Regeneron Pharmaceuticals, Inc. | $1,533 | 1 |
| ZIMLOVISERTIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| A Randomized, Double-Blind, Double-Dummy, Active-Comparator, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris | F. Hoffmann-La Roche AG | $1,191 | 1 |
| BREPOCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | GlaxoSmithKline, LLC. | $590.00 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF DUPILUMAB ON EXERCISE CAPACITY IN PATIENTS WITH MODERATE-TO-SEVERE ASTHMA | Regeneron Pharmaceuticals, Inc. | $565.66 | 2 |
| M19-130 | AbbVie, Inc. | $527.08 | 1 |
| RITLECITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| M19-990 | AbbVie, Inc. | $200.44 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 215 | 313 | $58,623 | $24,673 |
| 2022 | 2 | 197 | 289 | $44,720 | $22,629 |
| 2021 | 2 | 158 | 242 | $37,010 | $20,340 |
| 2020 | 3 | 151 | 182 | $21,260 | $8,620 |
Total Patients
721
Total Services
1,026
Medicare Billing
$76,262
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 175 | 273 | $45,614 | $20,635 | 45.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 40 | 40 | $13,009 | $4,038 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 164 | 256 | $35,975 | $19,053 | 53.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 33 | 33 | $8,745 | $3,576 | 40.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 134 | 218 | $30,650 | $17,547 | 57.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 24 | 24 | $6,360 | $2,793 | 43.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 113 | 144 | $13,392 | $5,726 | 42.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 11 | 11 | $2,915 | $1,236 | 42.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 16 | 16 | $3,413 | $923.38 | 27.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 11 | 11 | $1,540 | $734.59 | 47.7% |
About Dr. Victoria Werth, MD
Dr. Victoria Werth, MD is a Dermatology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689609281.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Victoria Werth, MD has received a total of $555,094 in payments from pharmaceutical and medical device companies, with $94,139 received in 2024. These payments were reported across 427 transactions from 38 companies. The most common payment nature is "Consulting Fee" ($417,373).
As a Medicare-enrolled provider, Werth has provided services to 721 Medicare beneficiaries, totaling 1,026 services with total Medicare billing of $76,262. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Dermatopathology
- Location Philadelphia, PA
- Active Since 07/11/2006
- Last Updated 04/02/2013
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1689609281
Products in Payments
- DUPIXENT (Biological) $62,768
- BENLYSTA (Biological) $19,925
- VYVGART (Drug) $17,750
- Rituxan (Biological) $11,799
- FASENRA (Biological) $11,532
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $10,814
- Hizentra (Biological) $9,436
- OCTAGAM (Biological) $5,847
- OCTAPLEX (Biological) $5,141
- Tremfya (Drug) $4,871
- Product in Development (Biological) $3,823
- LITFULO (Drug) $3,714
- COSENTYX (Biological) $3,600
- Otezla (Drug) $3,115
- SAPHNELO (Biological) $1,000
- Non-Covered Product (Drug) $783.00
- ORENCIA (Biological) $763.31
- STELARA (Biological) $630.00
- Korlym (Drug) $412.00
- LUPKYNIS (Drug) $99.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Philadelphia
Stephen Hess, Md, MD
Dermatology — Payments: $1.8M
Dermatology $1.8M
David Margolis, Md, MD
Dermatology — Payments: $1.1M
Dermatology $1.1M
Joel Gelfand, Md, MD
Dermatology — Payments: $787,044
Dermatology $787,044
Dr. Harold Farber, M.d,, M.D,
Dermatology — Payments: $484,640
Dermatology $484,640
Dr. Lawrence Parish, Md, MD
Dermatology — Payments: $406,273
Dermatology $406,273
Dr. Jules Lipoff, Md, MD
Dermatology — Payments: $294,407
Dermatology $294,407